These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 21838789)

  • 1. Single dose pharmacokinetics, pharmacodynamics, tolerability and safety of BAY 60-5521, a potent inhibitor of cholesteryl ester transfer protein.
    Boettcher MF; Heinig R; Schmeck C; Kohlsdorfer C; Ludwig M; Schaefer A; Gelfert-Peukert S; Wensing G; Weber O
    Br J Clin Pharmacol; 2012 Feb; 73(2):210-8. PubMed ID: 21838789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics, pharmacodynamics and safety of CKD-519, a CETP inhibitor, in healthy subjects.
    Kim CO; Oh ES; Choi C; Kim Y; Lee S; Kim S; Park MS
    Drug Des Devel Ther; 2016; 10():3763-3770. PubMed ID: 27895466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tolerability, pharmacokinetics and pharmacodynamics of TA-8995, a selective cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects.
    Ford J; Lawson M; Fowler D; Maruyama N; Mito S; Tomiyasu K; Kinoshita S; Suzuki C; Kawaguchi A; Round P; Boyce M; Warrington S; Weber W; van Deventer S; Kastelein JJ
    Br J Clin Pharmacol; 2014 Sep; 78(3):498-508. PubMed ID: 24628035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, tolerability and pharmacokinetics of dalcetrapib following single and multiple ascending doses in healthy subjects: a randomized, double-blind, placebo-controlled, phase I study.
    Derks M; Anzures-Cabrera J; Turnbull L; Phelan M
    Clin Drug Investig; 2011; 31(5):325-35. PubMed ID: 21366361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-dose pharmacokinetics and pharmacodynamics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects.
    Krishna R; Garg A; Panebianco D; Cote J; Bergman AJ; Van Hoydonck P; Laethem T; Van Dyck K; Chen J; Chavez-Eng C; Archer L; Lutz R; Hilliard D; Snyder K; Jin B; Van Bortel L; Lasseter KC; Al-Huniti N; Dykstra K; Gottesdiener K; Wagner JA
    Br J Clin Pharmacol; 2009 Oct; 68(4):535-45. PubMed ID: 19843057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of the cholesteryl ester transfer protein inhibitor evacetrapib on lipoproteins, apolipoproteins and 24-h ambulatory blood pressure in healthy adults.
    Suico JG; Wang MD; Friedrich S; Cannady EA; Konkoy CS; Ruotolo G; Krueger KA
    J Pharm Pharmacol; 2014 Nov; 66(11):1576-85. PubMed ID: 24961753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies.
    Krishna R; Anderson MS; Bergman AJ; Jin B; Fallon M; Cote J; Rosko K; Chavez-Eng C; Lutz R; Bloomfield DM; Gutierrez M; Doherty J; Bieberdorf F; Chodakewitz J; Gottesdiener KM; Wagner JA
    Lancet; 2007 Dec; 370(9603):1907-14. PubMed ID: 18068514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of a potentially effective dose in humans for BAY 60-5521, a potent inhibitor of cholesteryl ester transfer protein (CETP) by allometric species scaling and combined pharmacodynamic and physiologically-based pharmacokinetic modelling.
    Weber O; Willmann S; Bischoff H; Li V; Vakalopoulos A; Lustig K; Hafner FT; Heinig R; Schmeck C; Buehner K
    Br J Clin Pharmacol; 2012 Feb; 73(2):219-31. PubMed ID: 21762205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy, safety, tolerability, and pharmacokinetic profile of evacetrapib administered as monotherapy or in combination with atorvastatin in Japanese patients with dyslipidemia.
    Teramoto T; Takeuchi M; Morisaki Y; Ruotolo G; Krueger KA
    Am J Cardiol; 2014 Jun; 113(12):2021-9. PubMed ID: 24786356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cholesteryl Ester Transfer Protein Inhibition With Anacetrapib Decreases Fractional Clearance Rates of High-Density Lipoprotein Apolipoprotein A-I and Plasma Cholesteryl Ester Transfer Protein.
    Reyes-Soffer G; Millar JS; Ngai C; Jumes P; Coromilas E; Asztalos B; Johnson-Levonas AO; Wagner JA; Donovan DS; Karmally W; Ramakrishnan R; Holleran S; Thomas T; Dunbar RL; deGoma EM; Rafeek H; Baer AL; Liu Y; Lassman ME; Gutstein DE; Rader DJ; Ginsberg HN
    Arterioscler Thromb Vasc Biol; 2016 May; 36(5):994-1002. PubMed ID: 26966279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anthocyanin supplementation improves serum LDL- and HDL-cholesterol concentrations associated with the inhibition of cholesteryl ester transfer protein in dyslipidemic subjects.
    Qin Y; Xia M; Ma J; Hao Y; Liu J; Mou H; Cao L; Ling W
    Am J Clin Nutr; 2009 Sep; 90(3):485-92. PubMed ID: 19640950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases.
    Shinkai H
    Vasc Health Risk Manag; 2012; 8():323-31. PubMed ID: 22661899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of the cholesteryl ester transfer protein inhibitor, TA-8995, on cholesterol efflux capacity and high-density lipoprotein particle subclasses.
    van Capelleveen JC; Kastelein JJ; Zwinderman AH; van Deventer SJ; Collins HL; Adelman SJ; Round P; Ford J; Rader DJ; Hovingh GK
    J Clin Lipidol; 2016; 10(5):1137-1144.e3. PubMed ID: 27678430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia.
    Geisser P; Banké-Bochita J
    Arzneimittelforschung; 2010; 60(6a):362-72. PubMed ID: 20648928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics, Safety and Tolerability of Anacetrapib, a Novel Cholesteryl Ester Transfer Protein (CETP) Inhibitor, After Single and Multiple Doses in Healthy Chinese Subjects.
    Chen H; Chen W; Li H; Xu H; Yuan F; Sheng L; Liu C; Lin P; Yang M; Li X; Liu Y; Walker BM; Gheyas F; Iwamoto M; Stoch SA; Krishna R
    Adv Ther; 2021 Jul; 38(7):3973-3985. PubMed ID: 34101144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939--an oral, direct Factor Xa inhibitor--after multiple dosing in healthy male subjects.
    Kubitza D; Becka M; Wensing G; Voith B; Zuehlsdorf M
    Eur J Clin Pharmacol; 2005 Dec; 61(12):873-80. PubMed ID: 16328318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial.
    Nicholls SJ; Brewer HB; Kastelein JJ; Krueger KA; Wang MD; Shao M; Hu B; McErlean E; Nissen SE
    JAMA; 2011 Nov; 306(19):2099-109. PubMed ID: 22089718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure.
    Cao G; Beyer TP; Zhang Y; Schmidt RJ; Chen YQ; Cockerham SL; Zimmerman KM; Karathanasis SK; Cannady EA; Fields T; Mantlo NB
    J Lipid Res; 2011 Dec; 52(12):2169-2176. PubMed ID: 21957197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial.
    Hovingh GK; Kastelein JJ; van Deventer SJ; Round P; Ford J; Saleheen D; Rader DJ; Brewer HB; Barter PJ
    Lancet; 2015 Aug; 386(9992):452-60. PubMed ID: 26047975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple-dose pharmacodynamics and pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects.
    Krishna R; Bergman AJ; Jin B; Fallon M; Cote J; Van Hoydonck P; Laethem T; Gendrano IN; Van Dyck K; Hilliard D; Laterza O; Snyder K; Chavez-Eng C; Lutz R; Chen J; Bloomfield DM; De Smet M; Van Bortel LM; Gutierrez M; Al-Huniti N; Dykstra K; Gottesdiener KM; Wagner JA
    Clin Pharmacol Ther; 2008 Dec; 84(6):679-83. PubMed ID: 18580870
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.